Multimodal Biomarkers for Central Nervous System Disorders Development, Validation, and Clinical Integration: Proceedings of a Workshop
A key step towards reducing the burden of central nervous system (CNS) disorders is the identification of disease-specific biomarkers that can help predict, monitor, and guide treatment development. Recent technological advances have led to an increased number of biomarkers for different CNS disorde...
| Otros Autores: | , , |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Washington, DC :
National Academies Press
2023.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009815738806719 |
Tabla de Contenidos:
- The National Academies of SCIENCES • ENGINEERING • MEDICINE
- MULTIMODAL BIOMARKERS FOR CENTRAL NERVOUS SYSTEM DISORDERS PLANNING COMMITTEE
- FORUM ON NEUROSCIENCE AND NERVOUS SYSTEM DISORDERS
- Reviewers
- Acronyms and Abbreviations
- 1. Introduction and Background
- WORKSHOP OBJECTIVES
- ORGANIZATION OF PROCEEDINGS
- 2. Multimodal Biomarkers for Central Nervous System Disorders
- UNDERSTANDING THE IMPORTANCE OF MULTIMODAL BIOMARKERS TO PATIENTS
- UNDERSTANDING HOW MULTIMODAL BIOMARKERS FIT INTO FDA'S REGULATORY OVERSIGHT
- 3. Exploring the State of the Science of Multimodal Biomarkers for Central Nervous System Disorders
- ALZHEIMER'S DISEASE
- PARKINSON'S DISEASE
- HUNTINGTON'S DISEASE
- LESSONS LEARNED FOR DEVELOPING MULTIMODAL BIOMARKERS
- 4. Opportunities for Precision Medicine
- MEANINGFUL MEASURES: A PATIENT PERSPECTIVE
- PRECISION PSYCHIATRY
- PEDIATRIC NEURORADIOLOGY
- NEURODEVELOPMENTAL DISORDERS
- DIGITAL BEHAVIORAL BIOMARKERS
- MOVING TOWARD PRECISION MEDICINE IN CNS DISORDERS
- 5. Standardization and Methodology for Multimodal Biomarkers
- USING BIOMARKERS FOR PATIENT SELECTION IN NEW DRUG DEVELOPMENT
- METHODS FOR VALIDATION AND STANDARDIZATION
- RETHINKING CLINICAL TRIALS AND CLINICAL USE
- 6. Regulatory Decision Making
- BUILDING CONSORTIA FOR THE DEVELOPMENT OF MULTIMODAL BIOMARKERS
- DECISION MAKING AMONG REGULATORS AND PAYORS
- TRANSDIAGNOSTIC MULTIMODAL BIOMARKERS: A NEW CONCEPTUALIZATION OF DISEASE
- MULTIMODAL BIOMARKERS AND EXPLANABILITY
- 7. Exploring Opportunities to Move Forward
- VALUE OF MULTIMODAL BIOMARKERS
- IMPORTANCE OF DATA AND COLLABORATION
- CLINICAL INTEGRATION OF MULTIMODAL BIOMARKERS
- ACCESSIBILITY AND COST
- CONCLUDING REMARKS
- Appendix A. References
- Appendix B. Agenda.
